Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.88% | 42.50% | 86.74% | 39.26% | 48.67% |
| Total Depreciation and Amortization | 0.00% | -9.17% | -11.82% | -13.51% | -10.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.21% | -43.03% | -222.24% | -99.65% | -63.67% |
| Change in Net Operating Assets | -27.27% | 170.40% | -384.97% | -1,678.92% | 443.53% |
| Cash from Operations | -2.86% | 76.24% | 12.95% | 1.52% | 57.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 203.16% |
| Cash from Investing | -- | -- | -100.00% | -- | 202.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -93.00% | -- | 103.95% | 344.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 1,460.00% | -- | -3,440.00% |
| Cash from Financing | -47.41% | -93.00% | 696.84% | 104.16% | 330.62% |
| Foreign Exchange rate Adjustments | -100.00% | 100.00% | -- | -- | 66.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -450.10% | -3.04% | 80.60% | -105.03% | 106.85% |